Advertisement
Screener

ZAI LAB LIMITED (ZLAB) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

ZAI LAB LIMITED Capital Expenditures

ZAI LAB LIMITED (ZLAB) reported Capital Expenditures of $2.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06

  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $1.31M, a 54.63% decline year-over-year.
  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $1.20M, a 22.10% decline year-over-year.
  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $677.00K, a 73.96% decline year-over-year.
  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $3.00M, a 123.92% increase year-over-year.
  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for fiscal 2025 was $8.10M, a 43.20% increase from fiscal 2024.
  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for fiscal 2024 was $5.66M, a 21.56% decline from fiscal 2023.
  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for fiscal 2023 was $7.21M, a 70.67% decline from fiscal 2022.
  • ZAI LAB LIMITED payments to acquire property, plant, and equipment for fiscal 2022 was $24.59M, a 34.38% increase from fiscal 2021.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 9 month as first filedPayments to Acquire Property, Plant, and Equipment 12 monthPayments to Acquire Property, Plant, and Equipment 12 month as first filed
2026-06-30$1.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$2.50M
10-Q · filed 2026-08-06
$3.18M
derived: sum of 3 quarters · filed 2026-08-06
$6.19M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$1.20M
10-Q · filed 2026-05-07
$1.87M
derived: sum of 2 quarters · filed 2026-05-07
$4.88M
derived: sum of 3 quarters · filed 2026-05-07
$7.76M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$677.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$3.68M
derived: sum of 2 quarters · filed 2026-02-26
$6.57M
derived: sum of 3 quarters · filed 2026-08-06
$8.10M
10-K · filed 2026-02-26
2025-09-30$3.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$5.89M
derived: sum of 2 quarters · filed 2026-08-06
$7.42M
10-Q · filed 2025-11-06
$10.02M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$2.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$4.42M
10-Q · filed 2026-08-06
$7.02M
derived: sum of 3 quarters · filed 2026-08-06
$8.36M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$1.53M
10-Q · filed 2026-05-07
$4.13M
derived: sum of 2 quarters · filed 2026-05-07
$5.48M
derived: sum of 3 quarters · filed 2026-05-07
$6.22M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$2.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$3.94M
derived: sum of 2 quarters · filed 2026-02-26
$4.68M
derived: sum of 3 quarters · filed 2026-02-26
$5.66M
10-K · filed 2026-02-26
2024-09-30$1.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$2.08M
derived: sum of 2 quarters · filed 2025-11-06
$3.06M
10-Q · filed 2025-11-06
$3.28M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$741.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$1.72M
10-Q · filed 2025-08-07
$1.94M
derived: sum of 3 quarters · filed 2026-02-26
$3.69M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$974.00K
10-Q · filed 2025-05-08
$1.20M
derived: sum of 2 quarters · filed 2026-02-26
$2.95M
derived: sum of 3 quarters · filed 2026-02-26
$4.67M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$222.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$1.98M
derived: sum of 2 quarters · filed 2026-02-26
$3.70M
derived: sum of 3 quarters · filed 2026-02-26
$7.21M
10-K · filed 2026-02-26
2023-09-30$1.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$3.48M
derived: sum of 2 quarters · filed 2024-11-12
$6.99M
10-Q · filed 2024-11-12
$11.40M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$1.72M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$5.23M
10-Q · filed 2024-08-06
$9.65M
derived: sum of 3 quarters · filed 2025-02-27
$16.33M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$3.51M
10-Q · filed 2024-05-08
$7.93M
derived: sum of 2 quarters · filed 2025-02-27
$14.61M
derived: sum of 3 quarters · filed 2025-02-27
$18.36M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$4.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$11.10M
derived: sum of 2 quarters · filed 2025-02-27
$14.84M
derived: sum of 3 quarters · filed 2025-02-27
$24.59M
10-K · filed 2025-02-27
2022-09-30$6.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
$10.43M
derived: sum of 2 quarters · filed 2023-11-07
$20.17M
10-Q · filed 2023-11-07
$26.55M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30$3.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$13.49M
10-Q · filed 2023-08-07
$19.87M
derived: sum of 3 quarters · filed 2024-02-27
$26.14M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31$9.74M
10-Q · filed 2023-05-09
$16.12M
derived: sum of 2 quarters · filed 2024-02-27
$22.39M
derived: sum of 3 quarters · filed 2024-02-27
$26.36M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31$6.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
$12.65M
derived: sum of 2 quarters · filed 2024-02-27
$16.61M
derived: sum of 3 quarters · filed 2024-02-27
$18.30M
10-K · filed 2024-02-27
2021-09-30$6.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$10.23M
derived: sum of 2 quarters · filed 2022-11-09
$11.92M
10-Q · filed 2022-11-09
$11.92M
10-Q · filed 2021-11-09
$17.21M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$3.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$5.65M
10-Q · filed 2022-08-09
$10.94M
derived: sum of 3 quarters · filed 2023-03-01
$14.47M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$1.68M
10-Q · filed 2022-05-10
$6.98M
derived: sum of 2 quarters · filed 2023-03-01
$10.51M
derived: sum of 3 quarters · filed 2023-03-01
$10.77M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$5.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$8.83M
derived: sum of 2 quarters · filed 2023-03-01
$9.09M
derived: sum of 3 quarters · filed 2023-03-01
$10.13M
10-K · filed 2023-03-01
2020-09-30$3.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$3.79M
derived: sum of 2 quarters · filed 2021-11-09
$4.83M
10-Q · filed 2021-11-09
$6.62M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$260.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
$1.30M
10-Q · filed 2021-08-09
$3.09M
derived: sum of 3 quarters · filed 2022-03-01
$3.26M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$1.04M
10-Q · filed 2021-05-10
$2.83M
derived: sum of 2 quarters · filed 2022-03-01
$3.00M
derived: sum of 3 quarters · filed 2022-03-01
2019-12-31$1.78M
derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01
$1.96M
derived: sum of 2 quarters · filed 2022-03-01
$6.04M
10-K · filed 2022-03-01
2019-09-30$173.18K
derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21
$4.25M
6-K · filed 2020-01-21
2019-06-30$4.08M
6-K · filed 2020-09-11
2018-12-31$123.10K
derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01
$10.02M
10-K · filed 2021-03-01
$10.02M
20-F · filed 2019-03-29
2018-09-30$9.89M
6-K · filed 2020-01-21
2017-12-31$9.10M
20-F · filed 2020-04-29
$9.10M
20-F · filed 2018-04-30
2016-12-31$2.22M
20-F · filed 2019-03-29
2015-12-31$738.47K
20-F · filed 2018-04-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67